Entrada Therapeutics (TRDA) announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, MHRA, and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose, MAD, clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, DMD, in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA: